Interleukin-6 inhibition: a therapeutic strategy for the management of adult-onset Still’s disease

References

• Feist E, Mitrovic S, Fautrel B. Mechanisms, biomarkers and targets for adult-onset Still’s disease. Nat Rev Rheumatol. 2018;14(10):603–618.
   PubMed Web of Science ®Google Scholar
• Bywaters EG. Still’s disease in the adult. Ann Rheum Dis. 1971;30(2):121–133.
   PubMed Web of Science ®Google Scholar
• Jamilloux Y, Gerfaud-Valentin M, Martinon F, et al. Pathogenesis of adult-onset Still’s disease: new insights from the juvenile counterpart. Immunol Res. 2015;61(1–2):53–62. .
   PubMed Web of Science ®Google Scholar
• Kadavath S, Efthimiou P. Adult-onset Still’s disease-pathogenesis, clinical manifestations, and new treatment options. Ann. Med. 2015;47(1):6–14.
   PubMed Web of Science ®Google Scholar
• Gerfaud-Valentin M, Jamilloux Y, Iwaz J, et al. Adult-onset Still’s disease. Autoimmun Rev. 2014;13(7):708–722. .
   PubMed Web of Science ®Google Scholar
• Kaneko Y, Kameda H, Ikeda K, et al. Tocilizumab in patients with adult-onset still’s disease refractory to glucocorticoid treatment: a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis. 2018;77(12):1720–1729. .
   PubMed Web of Science ®Google Scholar
• Suematsu R, Ohta A, Matsuura E, et al. Therapeutic response of patients with adult Still’s disease to biologic agents: multicenter results in Japan. Mod Rheumatol. 2012;22(5):712–719. https://doi.org/10.3109/s10165-011-0569-6.
   PubMed Web of Science ®Google Scholar
• Nishina N, Kaneko Y, Kameda H, et al. The effect of tocilizumab on preventing relapses in adult-onset Still’s disease: a retrospective, single-center study. Mod Rheumatol. 2015;25(3):401–404.
   PubMed Web of Science ®Google Scholar
• Magadur-oly G, Billaud E, Barrier JH, et al. Epidemiology of adult Still’s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis. 1995;54(7):587–590. .
   PubMed Web of Science ®Google Scholar
• Wakai K, Ohta A, Tamakoshi A, et al. Estimated prevalence and incidence of adult Still’s disease: findings by a nationwide epidemiological survey in Japan. J. Epidemiol. 1997;7(4):221–225.
   PubMedGoogle Scholar
• Asanuma YF, Mimura T, Tsuboi H, et al. Nationwide epidemiological survey of 169 patients with adult Still’s disease in Japan. Mod Rheumatol. 2015;25(3):393–400. .
   PubMed Web of Science ®Google Scholar
• Magadur-Joly G, Billaud E, Barrier JH, et al. Epidemiology of adult Still’s disease: estimate of the incidence by a retrospective study in west France. Ann Rheum Dis. 1995;54(7):587–590. https://doi.org/10.1136/ard.54.7.587.
   PubMed Web of Science ®Google Scholar
• Evensen KJ, Nossent HC. Epidemiology and outcome of adult-onset Still’s disease in Northern Norway. Scand J Rheumatol. 2006;35(1):48–51.
   PubMed Web of Science ®Google Scholar
• Maruyama A, Kokuzawa A, Yamauchi Y, et al. Clinical features of elderly-onset adult-onset Still’s disease. Mod Rheumatol. 2020;13:1–7.
   Google Scholar
• Pouchot J, Sampalis JS, Beaudet F, et al. Adult Still’s disease: manifestations, disease course, and outcome in 62 patients. Medicine (Baltimore). 1991;70(2):118–136. .
   PubMed Web of Science ®Google Scholar
• Sugiura T, Maeno N, Kawaguchi Y, et al. A promoter haplotype of the interleukin-18gene is associated with juvenile idiopathic arthritis in the Japanese population. Arthritis Res Ther. 2006;8(3):R60.
   PubMed Web of Science ®Google Scholar
• Wang -F-F, Huang X-F, Shen N, et al. A genetic role for macrophage migration inhibitory factor (MIF) in adult-onset Still’s disease. ArthritisRes Ther. 2013;15(3):R65.
   PubMed Web of Science ®Google Scholar
• Fishman D, Faulds G, Jeffery R, et al. The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. J Clin Invest. 1998;102(7):1369–1376. .
   PubMed Web of Science ®Google Scholar
• Larson EB. Adult Still’ s disease-recognition of a clinical syndrome and recent experience. West J Med. 1985;142(5):665–671.
   PubMedGoogle Scholar
• Eft Himiou P, Paik PK, Bielory L. Diagnosis and management of adult onset Still ’ s disease. Ann Rheum Dis. 2006;65(5):564–572.
   PubMed Web of Science ®Google Scholar
• Takakuwa Y, Hanaoka H, Kiyokawa T, et al. Adult-onset Still’s disease-associated interstitial lung disease represents severe phenotype of the disease with higher rate of haemophagocytic syndrome and relapse. Clin Exp Rheumatol. 2019;37(6):23–27. Suppl.
   PubMed Web of Science ®Google Scholar
• Crispín JC, Martínez-Baños D, Alcocer-Varela J, et al. Adult-onset Still disease as the cause of fever of unknown origin. Medicine (Baltimore). 2005;84(6):331–337. .
   PubMed Web of Science ®Google Scholar
• Takahashi A, Abe K, Yokokawa J, et al. Clinical features of liver dysfunction in collagen diseases. Hepatol Res. 2010;40(11):1092–1097. .
   PubMed Web of Science ®Google Scholar
• Yamaguchi M, Ohta A, Tsunematsu T, et al. Preliminary criteria for classification of adult Still’s disease. J Rheumatol. 1992;19(3):424–430.
   PubMed Web of Science ®Google Scholar
• Fautrel B, Le Moël G, Saint-Marcoux B, et al. Diagnostic value of ferritin and glycosylated ferritin in adult onset Still’s disease. J Rheumatol. 2001;28(2):322–329.
   PubMed Web of Science ®Google Scholar
• Choe JY, Chung DS, Park SH, et al. Clinical significance of 18F-fluoro-dexoxyglucose positron emission tomography in patients with adult onset Still’s disease: report of two cases and review of literatures. Rheumatol Int. 2010;30(12):1673–1676.
   PubMed Web of Science ®Google Scholar
• Lebrun D, Mestrallet S, Dehoux M, et al. Validation of the Fautrel classification criteria for adult-onset Still’s disease. Semin. Arthritis Rheumatol. 2018;47(4):578–585.
   PubMed Web of Science ®Google Scholar
• Giacomelli R, Ruscitti P, Shoenfeld Y. A comprehensive review on adult onset Still’s disease. J Autoimmun. 2018;93:24–36.
   PubMed Web of Science ®Google Scholar
• Fujii T, et al. Cytokine and immunogenetic profiles in Japanese patients with adult Still’s disease. Association with chronic articular disease. Rheumatology (Oxford). 2001;40(12):1398–1404. .
   PubMed Web of Science ®Google Scholar
• Chen DY, Lan JL, Lin FJ, et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still’s disease. JRheumatol. 2004;31:2189–2198.
   PubMed Web of Science ®Google Scholar
• Ichida H, Kawaguchi Y, Sugiura T, et al. Clinical manifestations of Adult-onset Still’s disease presenting with erosive arthritis: association with low levels of ferritin and Interleukin-18. Arthritis Care Res (Hoboken). 2014;66(4):642–646. .
   PubMed Web of Science ®Google Scholar
• Choi JH, Suh CH, Lee YM, et al. Serum cytokine profiles in patients with adult onset Still’s disease. J Rheumatol. 2003;30(11):2422–2427.
   PubMed Web of Science ®Google Scholar
• Peckham D, Scambler T, Savic S, et al. The burgeoning field of innate immune-mediated disease and autoinflammation. J Pathol. 2017 Jan;241(2):123–139.
   PubMed Web of Science ®Google Scholar
• Chen DY, Lin CC, Chen YM, et al. Involvement of TLR7 MyD88-dependent signaling pathway in the pathogenesis of adult-onset Still’s disease. Arthritis Res Ther. 2013;15(2):R39.
   PubMed Web of Science ®Google Scholar
• Komiya A, Matsui T, Nogi S, et al. Neutrophil CD64 is upregulated in patients with active adult-onset Still’s disease, Scand. J Rheumatol. 2012;41:156–158.
   Web of Science ®Google Scholar
• Hsieh CW, Chen YM, Lin CC, et al. Elevated expression of the NLRP3 inflammasome and its correlation with disease activity in adult-onset still disease. J Rheumatol. 2017;44(8):1142–1150. .
   PubMed Web of Science ®Google Scholar
• Lee SJ, Cho YN, Kim TJ, et al. Natural killer T cell deficiency in active adult-onset Still’s disease: correlation of deficiency of natural killer T cells with dysfunction of natural killer cells. Arthritis Rheum. 2012;64(9):2868–2877. .
   PubMed Web of Science ®Google Scholar
• Hu Q, Shi H, Zeng T, et al. Increased neutrophil extracellular traps activate NLRP3 and inflammatory macrophages in adult-onset Still’s disease. Arthritis Res Ther. 2019;21(1):9.
   PubMed Web of Science ®Google Scholar
• Pay S, Türkçapar N, Kalyoncu M, et al. A multicenter study of patients with adult-onset Still’s disease compared with systemic juvenile idiopathic arthritis. Clin Rheumatol. 2006;25(5):639–644. .
   PubMed Web of Science ®Google Scholar
• Rau M, Schiller M, Krienke S, et al. Clinical manifestations but not cytokine profiles differentiate adult-onset Still’s disease and sepsis. J Rheumatol. 2010;37(11):2369–2376. .
   PubMed Web of Science ®Google Scholar
• Pascual V, Allantaz F, Arce E, et al. Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade. J Exp Med. 2005;201(9):1479–1486. .
   PubMed Web of Science ®Google Scholar
• Rooney T, Murphy E, Benito M, et al. Synovial tissue interleukin-18 expression and the response to treatment in patients with inflammatory arthritis. Ann Rheum Dis. 2004;63(11):1393–1398. .
   PubMed Web of Science ®Google Scholar
• Kishimoto T, Ishizaka K. Regulation of antibody response in vitro. VII. Enhancing soluble factors for IgG and IgE antibody response. J Immunol. 1973;111(4):1194–1205.
   PubMed Web of Science ®Google Scholar
• Choy EH, De Benedetti F, Takeuchi T, et al. Translating IL-6 biology into effective treatments. Nat Rev Rheumatol. 2020;16(6):335–345. .
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008;371(9617):998–1006. .
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner HI, Ruperto N, et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N Engl J Med. 2012;367(25):2385–2395. .
   PubMed Web of Science ®Google Scholar
• Yokota S, Imagawa T, Mori M, et al. Long-term treatment of systemic juvenile idiopathic arthritis with tocilizumab: results of an open-label extension study in Japan. Ann Rheum Dis. 2013;72(4):627–628. .
   PubMed Web of Science ®Google Scholar
• Miyamae T, Yokoya S, Yamanaka H, et al. Effect of tocilizumab on growth impairment in systemic juvenile idiopathic arthritis with long-term corticosteroid therapy. Mod Rheumatol. 2014;24(4):567–571.
   PubMed Web of Science ®Google Scholar
• De Benedetti F, Brunner H, Ruperto N, et al. Catch-up growth during tocilizumab therapy for systemic juvenile idiopathic arthritis: results from a phase III trial. Arthritis Rheumatol. 2015;67(3):840–848. .
   PubMed Web of Science ®Google Scholar
• Thonhofer R, Hiller M, Just H, et al. Treatment of refractory adult-onset Still’s disease with tocilizumab: report of two cases and review of the literature. Rheumatol Int. 2011;31(12):1653–1656. .
   PubMed Web of Science ®Google Scholar
• Puéchal X, DeBandt M, Berthelot J-M, et al. Tocilizumab in refractory adult Still’s disease. Arthritis Care Res. 2011;63(1):155–159. .
   PubMed Web of Science ®Google Scholar
• Cipriani P, Ruscitti P, Carubbi F, et al. Tocilizumab for the treatment of adult-onset Still’s disease: results from a case series. Clin Rheumatol. 2013;33(1):49–55. .
   PubMed Web of Science ®Google Scholar
• Sabnis GR, Gokhale YA, Kulkarni UP. Tocilizumab in refractory adult-onset Still’s disease with aseptic meningitis—efficacy of interleukin-6 blockade and review of the literature. Semin Arthritis Rheum. 2011;40(4):365–368.
   PubMed Web of Science ®Google Scholar
• Li T, Gu L, Wang X, et al. Publisher correction: a pilot study on tocilizumab for treating refractory adult-onset Still’s disease. Sci Rep. 2017;7(1):13477. .
   PubMed Web of Science ®Google Scholar
• Kır S, Özgen M, Zontul S. Adult-onset still’s disease and treatment results with tocilizumab. Int J Clin Pract. 2020;75(3):e13936.
   PubMed Web of Science ®Google Scholar
• Masui-Ito A, Okamoto R, Ikejiri K, et al. Tocilizumab for uncontrollable systemic inflammatory response syndrome complicating adult-onset Still disease: case report and review of literature. Medicine (Baltimore). 2017;96(29):e7596. .
   PubMed Web of Science ®Google Scholar
• Torigoe M, Maeshima K, Kuriyama Y, et al. Effectiveness of subcutaneous tocilizumab in refractory adult Still’s disease: report of three cases and a review of the literature. Mod Rheumatol Case Rep. 2021;9:1–11.
   Google Scholar
• Reihl Crnogaj M, Čubelić D, Babić A, et al. Treatment of refractory adult onset Still’s disease with tocilizumab-a single centre experience and literature review. Rheumatol Int. 2020 Aug;40(8):1317–1325. .
   PubMed Web of Science ®Google Scholar
• Ogata A, Tanimura K, Sugimoto T, et al. Phase III study of the efficacy and safety of subcutaneous versus intravenous tocilizumab monotherapy in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2014;66(3):344–354. .
   PubMed Web of Science ®Google Scholar
• Ogata A, Tanaka Y, Ishii T, et al. Long-term safety and efficacy of weekly subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis who had an inadequate response to subcutaneous tocilizumab every other week: results from the open-label extension of the SHINOBI study. Mod Rheumatol. 2019;29(5):767–774. .
   PubMed Web of Science ®Google Scholar
• Simeni Njonnou SR, Soyfoo MS, Vandergheynst FA. Efficacy of sarilumab in adult-onset Still’s disease as a corticosteroid-sparing agent. Rheumatology (Oxford). 2019;58(10):1878–1879.
   PubMed Web of Science ®Google Scholar
• Hu Q, Wang M, Jia M,J, et al. Tofacitinib in refractory adult-onset Still’s disease: 14 cases from a single centre in China. Ann Rheum Dis. 2020;79(6):842–844. .
   PubMed Web of Science ®Google Scholar
• Kacar M, Fitton J, Gough AK, et al. Mixed results with baricitinib in biological-resistant adult-onset Still’s disease and undifferentiated systemic autoinflammatory disease. RMD Open. 2020;6(2):6. .
   Web of Science ®Google Scholar
• Tarp S, Amarilyo G, Foeldvari I, et al. Efficacy and safety of biological agents for systemic juvenile idiopathic arthritis: a systematic review and meta-analysis of randomized trials. Rheumatology (Oxford). 2016;55(4):669–679. .
   PubMed Web of Science ®Google Scholar
• Park EH, Lee EY, Shin K, et al. Tocilizumab-induced anaphylaxis in patients with adult-onset Still’s disease and systemic juvenile idiopathic arthritis: a case-based review. Rheumatol Int. 2020;40(5):791–798.
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, et al. Macrophage activation syndrome in patients with systemic Juvenile Idiopathic arthritis under treatment with tocilizumab. J Rheumatol. 2015;42(4):712–722. .
   PubMed Web of Science ®Google Scholar
• Yokota S, Itoh Y, Morio T, et al. Tocilizumab in systemic juvenile idiopathic arthritis in a real-world clinical setting: results from 1 year of postmarketing surveillance follow-up of 417 patients in Japan. Ann Rheum Dis. 2016;75(9):1654–1660. .
   PubMed Web of Science ®Google Scholar
• Reiff A. Treatment of systemic juvenile idiopathic arthritis with tocilizumab – the role of anti-interleukin-6 therapy after a decade of treatment. Biol Ther. 2012 1;2(1):1. .
   PubMedGoogle Scholar
• Shimizu M, Mizuta M, Okamoto N, et al. Tocilizumab modifies clinical and laboratory features of macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatr Rheumatol Online J. 2020;18(1):2. .
   PubMed Web of Science ®Google Scholar
• Naniwa T, Uehara K, Yamabe T, et al. Reintroduction of tocilizumab elicited macrophage activation syndrome in a patient with adult-onset Still’s disease with a previous successful tocilizumab treatment. In: Mod rheumatol case rep. 2021. p. 1–5.
   Google Scholar
• Ohmura SI, Uehara K, Yamabe T, et al. Successful use of short-term add-on tocilizumab for refractory adult-onset still’s disease with macrophage activation syndrome despite treatment with high-dose glucocorticoids, cyclosporine, and etoposide. Mod Rheumatol Case Rep. 2020;4(2):202–207.
   PubMedGoogle Scholar
• Ajeganova S, De Becker A, Schots R. Efficacy of high-dose anakinra in refractory macrophage activation syndrome in adult-onset Still’s disease: when dosage matters in overcoming secondary therapy resistance. Ther Adv Musculoskelet Dis. 2020;12:1759720X20974858.
   PubMed Web of Science ®Google Scholar
• Sawhney S, Woo P, Murray KJ. Macrophage activation syndrome: a potentially fatal complication of rheumatic disorders. Arch Dis Child. 2001;85(5):421–426.
   PubMed Web of Science ®Google Scholar
• Behrens EM, Beukelman T, Paessler M, et al. Occult macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis. J Rheumatol. 2007;34(5):1133–1138.
   PubMed Web of Science ®Google Scholar
• Davì S, Consolaro A, Guseinova D, et al. An international consensus survey of diagnostic criteria for macrophage activation syndrome in systemic juvenile idiopathic arthritis. J Rheumatol. 2011;38(4):764–768. .
   PubMed Web of Science ®Google Scholar